The ZEISS Medical Ecosystem enables multiple layers of added value by connecting devices, data and applications to optimize clinical management of patients.
ZEISS today announced its new ZEISS Medical Ecosystem, a fully integrated environment where a combination of devices, data management, applications and services drive continuous improvement of patient outcomes. This ecosystem distinctively combines unsurpassed ocular expertise with leading-edge digital technology enabling evidence-based decisions that assure more efficient delivery of the highest quality of care in a single and secure platform.
'At ZEISS, the core of our business strategy is shaping healthcare with new technologies in order to advance medicine,' said Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG. 'With the ZEISS Medical Ecosystem, we are uniquely positioned to drive the digital transformation of ophthalmology working with external partners, including customers, healthcare providers and digital innovators.'
'This fully-connected platform will continue to expand our integrated workflow solutions, adding value for the customer and enabling new ways to maximize clinical efficiency and performance,' said Euan S. Thomson, PhD, President of Ophthalmic Devices and Head of the Digital Business Unit for Carl Zeiss Meditec. 'The power of digital technologies, data management and a range of new applications will create an environment of connectivity, automation, artificial intelligence, and safe and efficient management of data, enabling improved results for patients. I truly believe that the digital ecosystem will provide opportunities to improve the efficiency of healthcare delivery and ultimately, quality of life for our customers' patients.'
The ZEISS Medical Ecosystem makes digital adoption easy, providing one ecosystem connecting devices, data and applications that enable a streamlined workflow, clinical planning, education, and optimization of clinical procedures. It opens possibilities for the creation of new solutions, where data passes seamlessly from one ZEISS device to another using artificial-intelligence-powered applications and software tools.
'In our clinical environment, data management and efficient workflows can be a challenge,' said Ranya Habash, MD, distinguished surgeon and assistant professor of ophthalmology at the Bascom Palmer Eye Institute, where she also serves as medical director of technology innovation. 'So combining new ZEISS technologies with our existing equipment, even from other providers, allows for more accessible data and helps me provide better care to my patients.'
With the ZEISS integrated portfolio of diagnostic and therapeutic devices supported by a cloud-based digital platform, the ZEISS Medical Ecosystem delivers value beyond the devices with a fully connected and integrated approach that is unsurpassed in the medical industry.
For more information, visit www.zeiss.com/med.
Contact for investors
Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
investors.meditec@zeiss.com
Laurie Ferguson
Head of Global Communications Ophthalmic Devices
Carl Zeiss Meditec
Phone: +1 925 719 7825
laurie.ferguson@zeiss.com
Brief Profile
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 3,290 employees worldwide, the Group generated revenue of EUR1,335.5m in fiscal year 2019/20 (as of 30 September 2020).
The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG's shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.
For further information visit: www.zeiss.com/med
CARL ZEISS MEDITEC AG 
